Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of Mounjaro (tirzepatide), and for many people it peaks in the first day or two after an injection before fading as the week goes on. It tends to be most noticeable at the start of treatment and after each dose increase, then settles as your body adjusts. These are prescription-only medicines, and a clinician assesses your suitability before treatment begins — which is also when it's worth raising any concerns about tolerability. The NHS medicines page for tirzepatide confirms nausea as a common side effect and offers straightforward guidance on when it's worth seeking further help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro activates both GIP and GLP-1 receptors, and one of the effects shared by both pathways is slower gastric emptying. Your stomach holds on to food longer than it normally would. That delay is part of why appetite reduces so reliably (you feel full on less) but it also explains the queasiness that follows a meal, especially a large or fatty one.
The sensation is real. It is not anxiety, and it is not a sign that something has gone wrong. It is your digestive system adapting to a different pace of working. The NHS tirzepatide guidance describes nausea, vomiting, diarrhoea, constipation, and indigestion as common effects, meaning they are reported by a meaningful proportion of people, not by one or two.
Knowing the mechanism helps with the management: if food is moving slowly, putting in a lot of food quickly will make things worse. Every step that follows from here is essentially a way of working with that slower pace rather than against it. You can read a broader overview of Mounjaro's side-effect profile if you want the fuller picture beyond nausea alone.
The single most effective change most people make is reducing portion size. A plate that looked ordinary before treatment may now be too much for a stomach that is emptying more slowly. Eating to about 70–80% of your usual amount, pausing, and waiting before deciding on more is a reasonable starting point.
Fat and rich foods slow gastric emptying further on top of what the medicine is already doing. Plain carbohydrates, lean protein, cooked vegetables, and soups tend to sit more comfortably. Fizzy drinks and anything very sweet or greasy are worth avoiding on injection day and the day after.
Timing matters too. Many people inject their Mounjaro on the same evening each week and find that eating a light meal beforehand (rather than on an empty stomach or a very full one) makes the following morning easier. If your pen lives in the fridge door, pairing the injection with an existing routine (checking it as you put the milk away, for instance) can help you keep to a consistent schedule, which in turn makes side effects more predictable.
More detail on nausea specifically after eating on Mounjaro is available if meals are your main trigger.
Mild to moderate nausea is expected and, for most people, manageable. What should not be waited out is vomiting severe enough that you cannot keep fluids down for more than a day, or sharp, persistent pain in your upper abdomen that spreads toward your back. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, the signature symptom is exactly that kind of deep, radiating stomach pain, with or without vomiting. If you experience it, seek urgent medical help rather than attributing it to ordinary nausea.
Signs of dehydration (dark urine, dizziness when standing, inability to keep sips of water down) also warrant a call to your GP or 111. Severe GI illness can affect kidney function if fluids are not replaced, and that risk is not unique to Mounjaro but applies whenever vomiting is prolonged.
If you are uncertain whether what you are experiencing is within the expected range, your prescriber or our aftercare team are the right first contact. If you want guidance written specifically around this medicine, our page on feeling sick on Mounjaro covers additional strategies beyond dietary changes, as does our companion guide on feeling sick on tirzepatide for anyone who finds it useful to read about the active ingredient directly. There is also a practical guide to reducing nausea on Mounjaro that covers additional strategies beyond dietary changes.
Nausea at the 2.5mg starting dose is rarely severe, because that dose exists specifically as a tolerability phase) the goal is adjustment, not maximum effect. Side effects tend to return, often more intensely, when the dose increases. This is expected and usually brief, but it is the reason dose steps are spaced several weeks apart rather than rushed.
If nausea is still disrupting your daily life after three to four weeks at a given dose, that is worth raising with your prescriber before moving up. It is clinically reasonable to stay at a lower dose for longer. Pushing through persistent vomiting to reach a higher dose faster is not a strategy that benefits anyone. Your prescriber can advise on whether a slower schedule suits you better. The question of why nausea often peaks specifically after the injection itself is covered separately if that pattern is what you are noticing.
Mounjaro is a prescription medicine, and decisions about titration always sit with the clinician reviewing your case. If you are still working out whether treatment is right for you, the consultation page is the place to start, a GPhC-registered prescriber reviews every application, and any tolerability concerns you raise will be part of that clinical picture.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.